This is a multiple-part series. Join the email list to be notified when each article is published:

+ Why We Are Investigating the Link Between Fibroids, Keloids, and Hair Loss (And Why We Need an Illustrator to Do It). Read here.

+ CCCA Patient Education That Actually Changes Behavior: Moving Beyond "Stop Wearing Tight Braids". Read here.

+ CCCA Is No Longer a "There's Not Much We Can Do" Diagnosis. Read here.

+ Clinical Pearls: Key Teaching Points for Patient Education. Read here.

+ DNP and PhD Nurse Scientist Research Ideas. Read here.

+ Entrepreneurial Opportunities and Business Strategies

‍

‍

‍

‍

‍

DNP PRO

The gaps in CCCA research and clinical care offer numerous opportunities for practice-based doctoral projects that could meaningfully advance the field. Here are three distinct project types aligned with different DNP focus areas:

‍

QUALITY IMPROVEMENT PROJECT: Standardizing CCCA Screening and Early Intervention in Primary Care Settings

Background: CCCA is consistently diagnosed at later stages than optimal for therapeutic intervention. Most patients present with stage 3-5 disease by the time they reach dermatology, despite having symptoms for years. Primary care providers and general practice NPs see these patients regularly but lack standardized screening protocols and referral pathways.

Project Aim: Develop and implement a scalp screening protocol for use in primary care settings serving populations at high risk for CCCA, with defined criteria for dermatology referral and treatment initiation.

Implementation Strategy: Create a simple validated screening tool based on patient-reported symptoms (unexplained crown hair breakage, progressive vertex thinning, scalp tenderness) combined with basic clinical examination findings (perifollicular erythema, grayish halos, centrifugal pattern). Train primary care staff to perform brief scalp examinations during annual wellness visits for Black women over age 25. Establish clear referral pathways to dermatology for positive screens, and develop protocols for primary care-initiated treatment with topical corticosteroids and doxycycline while awaiting specialty evaluation.

Outcome Measures: Percentage of eligible patients screened, number of new CCCA diagnoses identified, average disease stage at diagnosis (pre- vs. post-implementation), time from symptom onset to diagnosis, patient satisfaction scores, and rates of early treatment initiation.

Sustainability: Integration into annual wellness visit templates, ongoing staff education, partnership with local dermatology practices for streamlined referrals.

‍

EVIDENCE-BASED PRACTICE PROJECT: Comparative Effectiveness of Topical Metformin vs. Standard Therapy in CCCA

Background: Case reports demonstrate substantial hair regrowth with topical metformin in patients with refractory CCCA, but no comparative effectiveness data exists. Standard therapy (intralesional corticosteroids + topical steroids + oral doxycycline) has modest efficacy, with most patients experiencing disease stabilization rather than regrowth. Topical metformin targets the fibroproliferative pathway specifically but requires compounding and has not been systematically evaluated.

Project Aim: Compare clinical outcomes, patient-reported outcomes, and safety profiles between topical metformin and standard therapy in patients with active CCCA over six months of treatment.

Implementation Strategy: Recruit 30-40 patients with biopsy-confirmed active CCCA and randomize to receive either (1) topical 10% metformin cream daily or (2) standard therapy (monthly intralesional triamcinolone 5mg/mL + topical clobetasol 0.05% ointment twice weekly + oral doxycycline 100mg daily). Assess participants at baseline, 3 months, and 6 months with standardized photography, hair density counts in defined areas, Central Hair Loss Grading scale scores, dermoscopy, and validated quality of life measures (Dermatology Life Quality Index, Hair-Specific Skindex-29).

Outcome Measures: Primary outcome: change in hair density at 6 months. Secondary outcomes: change in Central Hair Loss Grading scale score, patient-reported symptom improvement, quality of life improvement, treatment adherence rates, adverse effects, and patient preference at study completion.

Translation to Practice: If topical metformin demonstrates superior efficacy, results could support insurance coverage requests and development of commercial formulations. If equivalence is shown, patient preference and side effect profiles could guide individualized treatment selection.

‍

POLICY-FOCUSED INITIATIVE: Addressing Insurance Coverage Barriers for CCCA Treatments

Background: Many effective CCCA therapies face insurance coverage barriers: compounded topical metformin is typically not covered; JAK inhibitors approved for rheumatoid arthritis and alopecia areata face prior authorization hurdles for off-label CCCA use; genetic testing for PADI3 mutations isn't covered; maintenance therapy needed for chronic disease management is denied as "cosmetic." These barriers disproportionately affect Black women, who face existing disparities in dermatologic care access.

Project Aim: Document the extent of insurance coverage barriers for evidence-based CCCA treatments and develop an advocacy toolkit to support clinicians in obtaining coverage for their patients.

Implementation Strategy: Survey 100 dermatology and advanced practice providers treating CCCA to document: (1) insurance denial rates for specific therapies, (2) time burden of prior authorization processes, (3) out-of-pocket costs for patients, (4) treatment modifications made due to coverage barriers, and (5) impact on clinical outcomes when first-line therapy is denied. Compile successful prior authorization letters, appeal templates, and literature summaries supporting medical necessity of specific treatments. Partner with dermatology specialty organizations to develop policy position statements on CCCA treatment coverage. Engage patient advocacy groups to share stories illustrating the impact of coverage denials on quality of life and disease progression.

Outcome Measures: Number of providers utilizing advocacy toolkit, documented cases of successful coverage appeals using toolkit resources, changes in insurance coverage policies for specific therapies, engagement of specialty societies in policy advocacy, and patient outcomes when coverage barriers are overcome versus when patients forego treatment due to cost.

Policy Impact: Development of position statements and coverage recommendations from specialty societies, provider testimony to insurance medical directors supporting coverage expansion, and documentation of health disparities created by coverage barriers to support policy interventions.

‍

‍

STEP-BY-STEP IMPLEMENTATION GUIDE: FROM DIAGNOSIS TO TREATMENT

Translating CCCA research into clinical practice requires a systematic approach. Here's an evidence-based clinical pathway from diagnosis through long-term management:

‍

Step 1: Recognize and Diagnose (Weeks 0-2)

When a patient presents with progressive hair loss, especially a Black woman with vertex thinning, obtain a focused history. Key elements include: when changes were first noticed, whether hair is breaking or falling from the root, presence of scalp symptoms (itching, burning, tenderness), family history of similar hair loss, and documentation of current hair care practices (relaxer use and frequency, typical hairstyles and duration, heat styling frequency and temperatures, product regimen).

Perform a complete scalp examination under good lighting. Look for: centrifugal pattern of hair loss starting at crown/vertex, perifollicular erythema or scaling, follicular dropout in affected areas, and preserved follicular openings versus smooth scarred scalp. Use dermoscopy to identify: perifollicular halos, polytrichia, and decreased follicular ostia.

If clinical suspicion is high, perform a 4mm punch biopsy from the active border of hair loss where pathology is expected to be most informative. Submit for horizontal sectioning with request for assessment of follicular density, perifollicular inflammation, follicular degeneration, and fibrosis. Document disease stage using the Central Hair Loss Grading scale (0-5) and photograph the scalp for baseline comparison.

‍

Step 2: Patient Education and Goal Setting (Week 2)

Once diagnosis is confirmed, schedule dedicated time for education. Use evidence-based teaching points to explain CCCA as a chronic fibroproliferative condition with genetic susceptibility, triggered by mechanical stress and inflammation. Set realistic expectations about timelines for improvement (3-6 months for visible regrowth), the need for long-term management, and the importance of treatment adherence.

Establish patient-specific goals. Some patients prioritize stopping progression at all costs; others want regrowth in specific areas for particular hairstyles; others prioritize symptom relief over cosmetic improvement. Understanding patient priorities helps tailor treatment recommendations and define success metrics.

‍

Step 3: Initiate Evidence-Based Treatment (Weeks 2-4)

For patients with early-stage active disease, standard first-line therapy includes: intralesional triamcinolone 5mg/mL to affected areas monthly (as used in published case reports), topical clobetasol 0.05% ointment or solution applied to affected areas twice weekly between injections, oral doxycycline 100mg daily for anti-inflammatory benefit, and gentle scalp care recommendations to minimize mechanical trauma.

For patients who have already failed conventional approaches or who present with moderate-to-severe disease, consider mechanism-based therapies: topical metformin 10% cream daily (compounded formulation as described in Araoye et al. 2020), oral JAK inhibitor therapy if appropriate (baricitinib 4mg daily as reported in Workman & Kindred 2023, after obtaining baseline CBC, comprehensive metabolic panel, lipid panel, and tuberculosis screening), or combination approaches based on disease severity and patient factors.

‍

Step 4: Monitor Response and Adjust (Months 1-6)

Follow-up visits every 6-8 weeks during initial treatment phase allow for systematic monitoring. At each visit: photograph affected areas using consistent lighting and positioning, perform dermoscopy to assess for signs of disease activity versus stabilization, document symptoms and treatment adherence, and record any side effects.

Use structured assessment such as the Global Photographic Assessment to grade improvement as: worsening (increased hair loss or inflammation), stable (no change), improved (decreased hair loss/inflammation or early regrowth), or marked improvement (substantial regrowth or complete stabilization). This structured assessment guides decisions to continue current therapy, escalate treatment, or modify the approach.

If adequate response hasn't occurred by 3 months, reassess the diagnosis (repeat biopsy if indicated), verify treatment adherence, and consider treatment escalation. This might involve switching from topical to oral therapy, adding a second mechanism-based agent, or referring for clinical trial enrollment if available.

‍

Step 5: Transition to Maintenance and Long-Term Management (Months 6+)

Once stability or regrowth is achieved, the goal shifts to maintaining gains with the least intensive therapy possible. Some patients can reduce injection frequency from monthly to every 6-8 weeks, transition from daily oral medication to as-needed topical therapy, or decrease the potency of topical corticosteroids.

However, research on CCCA natural history indicates most patients require some ongoing treatment indefinitely. Complete treatment discontinuation often leads to recurrence. The clinical goal is sustainable long-term management with the minimum effective therapy intensity, not cure.

Throughout this pathway, continue reinforcing gentle hair care practices and adjusting treatment based on patient goals and tolerability. Document all interventions, responses, and rationale for treatment changes to create a comprehensive clinical record.

‍

PHD NURSE RESEARCH OPPORTUNITIES

While my DNP colleagues focus on translating existing evidence into practice, PhD-prepared nurse scientists have critical opportunities to generate new knowledge about CCCA through rigorous research. The current evidence base, though growing, has significant gaps that well-designed studies could address.

‍

Priority Research Gap #1: Molecular Mechanisms Linking Mechanical Stress to Fibroproliferative Response

We know mechanical stress triggers CCCA in genetically susceptible individuals, but the molecular mechanisms connecting physical tension on hair follicles to pathologic fibrosis remain poorly understood. How does mechanical force on the follicle activate inflammatory signaling? What mechanotransduction pathways are involved? Why do some individuals mount an appropriate healing response while others develop progressive fibrosis?

Potential PhD Dissertation Topic: "Mechanotransduction Pathways in Hair Follicle Epithelium: Investigating YAP/TAZ Signaling in CCCA Pathogenesis." This research could use in vitro follicle organ culture systems to apply controlled mechanical stress and examine activation of mechanosensitive transcription factors, changes in gene expression profiles, and effects of pathway-specific inhibitors on fibrotic responses.

‍

Priority Research Gap #2: The Microbiome's Role in CCCA Progression

Emerging evidence suggests the scalp microbiome influences inflammatory skin conditions, yet no comprehensive studies have characterized the microbiome in CCCA scalps or investigated whether dysbiosis contributes to disease progression. Do CCCA patients have distinct microbial populations compared to healthy controls? Does the microbiome differ between active versus burned-out disease? Could microbiome-targeted interventions modulate disease activity?

Potential PhD Dissertation Topic: "Scalp Microbiome Profiling in Central Centrifugal Cicatricial Alopecia: Associations with Disease Activity and Fibrotic Markers." This work could use 16S rRNA sequencing of scalp swabs from CCCA patients at different disease stages, correlate microbial diversity and composition with clinical and histopathologic markers of disease activity, and explore whether specific bacterial populations correlate with treatment response.

‍

Priority Research Gap #3: Genetic Architecture Beyond PADI3

While PADI3 mutations account for approximately 24% of CCCA cases, the genetic basis for the remaining 76% is unknown. The disease shows clear familial clustering and population-specific prevalence patterns, suggesting a strong genetic component not yet identified. What other genes contribute to CCCA susceptibility? Are there gene-environment interactions that modulate penetrance? Can we identify genetic markers that predict treatment response?

Potential PhD Dissertation Topic: "Whole Genome Sequencing to Identify Novel Susceptibility Loci for Central Centrifugal Cicatricial Alopecia in the African Diaspora." This research would require collaboration with genetic epidemiologists and access to well-phenotyped patient cohorts and ancestry-matched controls, but could identify new therapeutic targets and improve our understanding of disease heterogeneity.

‍

Priority Research Gap #4: Psychosocial Impact and Quality of Life

Despite the profound psychological burden of progressive permanent hair loss, no validated CCCA-specific quality of life instrument exists. Generic dermatology QOL measures don't capture the specific concerns relevant to Black women with CCCA, including cultural factors around hair and identity, the trauma of being blamed for one's condition, and the social and economic impact of hair loss in communities where hair carries particular cultural meaning.

Potential PhD Dissertation Topic: "Development and Validation of the CCCA Quality of Life Scale: A Mixed-Methods Approach to Understanding Patient-Reported Outcomes." This work could use qualitative interviews with CCCA patients to identify relevant QOL domains, develop and refine questionnaire items through cognitive interviewing, and validate the instrument through psychometric testing in a large diverse sample.

‍

Priority Research Gap #5: Treatment Optimization and Comparative Effectiveness

We have emerging evidence for several therapeutic approaches in CCCA, but almost no head-to-head comparative data and no studies examining combination therapy systematically. What's the optimal first-line treatment? When should we escalate to mechanism-based therapy? Are there predictors of treatment response that could guide personalized therapy selection?

Potential PhD Dissertation Topic: "Predictors of Treatment Response in Central Centrifugal Cicatricial Alopecia: A Multi-Site Prospective Cohort Study." This research could follow CCCA patients receiving standardized treatment protocols, collect detailed baseline data (clinical, histopathologic, genetic), and identify baseline characteristics associated with treatment response to develop a predictive model for treatment selection.

‍

‍

About the Author

Dr. Kimberly Madison, DNP, AGPCNP-BC, WCC, is a Board-Certified, Doctorally-prepared Nurse Practitioner, educator, and author dedicated to advancing dermatology nursing education and research with an emphasis on skin of color. As the founder of Mahogany Dermatology Nursing | Education | Research™ and the Alliance of Cosmetic Nurse Practitioners™, she expands access to dermatology research, business acumen, and innovation while also leading professional groups and mentoring clinicians. Through her engaging and informative social media content and peer-reviewed research, Dr. Madison empowers nurses and healthcare professionals to excel in dermatology and improve patient care.

‍

‍

References

Araoye, E. F., Thomas, J. A. L., & Aguh, C. U. (2020). Hair regrowth in 2 patients with recalcitrant central centrifugal cicatricial alopecia after use of topical metformin. JAAD Case Reports, 6(2), 106–108. https://doi.org/10.1016/j.jdcr.2019.12.008

Heath, C. R. (2024). Part 1: Scalp and hair disorders in patients with skin of color [Presentation slides]. Dermatology Week APP Institute.

Lin, C. M. A., Cooles, F. A. H., & Isaacs, J. D. (2020). Basic mechanisms of JAK inhibition. Mediterranean Journal of Rheumatology, 31(Suppl 1), 100–104. https://doi.org/10.31138/mjr.31.1.100

Malki, L., Sarig, O., Romano, M. T., Méchin, M.-C., Peled, A., Pavlovsky, M., Warshauer, E., Samuelov, L., Uwakwe, L., Briskin, V., Mohamad, J., Gat, A., Isakov, O., Rabinowitz, T., Shomron, N., Adir, N., Simon, M., McMichael, A., Dlova, N. C., ... Sprecher, E. (2019). Variant PADI3 in central centrifugal cicatricial alopecia. New England Journal of Medicine, 380(9), 833–841. https://doi.org/10.1056/NEJMoa1816614

Ogunleye, T. A., McMichael, A., & Olsen, E. A. (2014). Central centrifugal cicatricial alopecia: What has been achieved, current clues for future research. Dermatologic Clinics, 32, 173–181. https://doi.org/10.1016/j.det.2013.12.005

Senna, M., Taylor, S., Piraccini, B., Shapiro, J., Somani, N., Jedynak, J., Ogwu, S., Buchanan, A., Craiglow, B., & Ohyama, M. (2024). Characterizing loss of response occurring in a small number of patients during 3 years of long-term maintenance therapy with baricitinib 4-mg: Results from BRAVE-AA1 and -AA2 trials [Poster presentation]. American Academy of Dermatology Annual Meeting. doi:10.25251/skin.9.supp.522

Workman, K., & Kindred, C. (2023). Hair regrowth in a patient with central centrifugal cicatricial alopecia after a 2-month trial of baricitinib. JAAD Case Reports, 39, 109–111. https://doi.org/10.1016/j.jdcr.2023.07.016

‍